Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$507.42 USD

507.42
849,492

+1.08 (0.21%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Luminex (LMNX) Misses on Earnings in Q2, Margins Contract

Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.

    Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag

    We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.

      Henry Schein's (HSIC) Q2 Earnings Beat, '18 EPS View Up

      All four of Henry Schein's (HSIC) operating segments recorded strong year-over-year growth in Q2.

        Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates

        Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.

          Cardinal Health (CAH) Surpasses Earnings Estimates in Q4

          Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.

            Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand

            Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.

              Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates

              Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.

                Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y

                Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.

                  Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates

                  We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q2, driven by solid performances in the United States and internationally.

                    ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth

                    ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.

                      Pacific Biosciences (PACB) Loss In Line With Estimates in Q2

                      Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.

                        DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View

                        Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.

                          Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid

                          Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.

                            CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance

                            CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.

                              Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance

                              Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.

                                DaVita (DVA) Beats Earnings and Revenue Estimates in Q2

                                Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q2.

                                  Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3

                                  Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.

                                    PRA Health's (PRAH) Q2 Earnings Top, Revenues Lag Estimates

                                    PRA Health (PRAH) sees year-over-year double-digit growth in earnings, revenues and net new business in Q2. However, increasing labor-related costs in the Clinical Research wing is a concern.

                                      Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall

                                      Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.

                                        AmerisourceBergen (ABC) Beats on Q3 Earnings & Revenues

                                        AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q3.

                                          PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up

                                          Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.

                                            IDEXX Laboratories (IDXX) Beats on Q2 Earnings, EPS View Up

                                            IDEXX Laboratories' (IDXX) stellar performance in Q2 was driven by strong sales at the CAG business.

                                              NuVasive (NUVA) Q2 Earnings Meet Estimates, EPS View Down

                                              NuVasive (NUVA) expects robust demand for recently-launched products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market.

                                                Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips

                                                At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.

                                                  Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3

                                                  Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.